Venlafaxine in treatment-resistant major depression: A Canadian multicenter, open-label trial

Journal of Clinical Psychopharmacology

Volumn 19, Issue 5, 1999, Pages 401-406

  De Montigny, Claude ^a   Silverstone, Peter H ^b   Debonnel, Guy ^a   Blier, Pierre ^a   Bakish, David ^c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMOXAPINE; BUSPIRONE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; IPSAPIRONE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; CANADA; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIAPHORESIS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; MALE; MULTICENTER STUDY; NAUSEA; PATIENT SELECTION; PRIORITY JOURNAL; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CANADA; CYCLOHEXANOLS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES;

EID: 0032842390     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199910000-00003     Document Type: Article

References (20)

1. Dinan T. Treatment approaches to therapy-resistant depression. J Psychopharmacol 1995;9[suppl]:199-204.
2. Thase ME, Rush AJ, Kasper S, Nemeroff CB. Tricyclics and newer antidepressant medications: treatment options for treatment-resistant depressions. Depression 1995;2:152-68.
3. Keller MB, Harrison W, Fawcett JA, Gelenberg A, Hirschfeld RMA, Klein D, Kocsis JH, McCullough JP, Rush AJ, Schatzberg A, Thase ME. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacol Bull 1995; 31:205-12.
4. Lydiard RB. Tricyclic-resistant depression: treatment resistance or inadequate treatment? J Clin Psychiatry 1985;46:412-17.
5. Thase ME, Kupfer DJ. Characteristics of treatment-resistant depression. In: Zohar J, Belmaker RH, eds. Treating resistant depression. New York: PMA Publishing Co., 1987:23-45.
6. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RMA, Shea T. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-16.
7. Dinan TG, Burnett F. Venlafaxine pharmacology, clinical efficacy and tolerability of a serotonin-noradrenaline reuptake inhibitor. J Serotonin Res 1997;3:203-21.
8. Clerc GE, Ruimy P, Verdeau-Paillès J, on behalf of the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalised for major depression and melancholia. Int Clin Psychopharmacol 1994;9: 139-43.
9. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-23.
10. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
11. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-89.
12. Guy W. ECDEU assessment manual for psychopharmacology, revised. Department of Health, Education, and Welfare, Publication no. (ADM)76-338. Rockville, MD: National Institutes of Mental Health, 1976.
13. Beasley CM, Sayler ME, Cunningham GE, Weiss AM, Masica DN. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 1990;20:193-200.
14. Nierenberg AA, Price LH, Charney DS, Heninger GR. After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression. J Affect Disord 1990;18:167-75.
15. Reimherr FW, Woods DR, Byerley B, Brainard J, Grosser BI. Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984;20:70-2.
16. Charney DS, Price LH, Heninger GR. Desipramine-yohimbine combination treatment of refractory depression. Arch Gen Psychiatry 1986;43:155-61.
17. Delgado PL, Price LH, Charney DS, Heninger GR. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 1988;15:55-60.
18. Nolen WA, Van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Haffmans J. Treatment strategy in depression. I. Nontricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 1988;78:668-75.
19. Klerman GL, Weissman MM, Frank E, Kocsis JH, Markowitz JC, Montgomery S. Evaluating drug treatments of depressive disorders. In: Prien RF, Robinson DS. Clinical evaluation of psychotropic drugs: principles and guidelines. New York: Raven Press, 1994:281-325.
20. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996;41:201-10.